Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Fri, Dec 5th, 2025

Biotechnology Stocks

A list of publicly traded biotechnology and biotech-related stocks and ETFs.
Fri, Dec 5th, 2025

Biotechnology (biotech) Stocks are publicly traded companies that develop pharmaceutical drugs used in the treatment of disease. You can use Barchart's Biotech Stocks list to find investment opportunities and compare stocks involved in this hot industry.

View Profiles of these companies.

Biotechnology Stocks News

Can Biotech’s Top 5 Revive the Sector’s Pulse?

Biotech is stirring again as M&A and approvals rise. Trade volatility in the sector’s top five leaders with leverage through Direxion’s TBXU ETF.

Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

With one blockbuster product, this biotech is gearing up for more product launches next year.

$SPX : 6,857.12 (+0.11%)
BBIO : 74.76 (+0.82%)
This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday....

BNR : 20.55 (-9.67%)
The Short-Sellers May Be Right About This Red-Hot Pharma Stock

Palvella Therapeutics (PVLA) is a clinical-stage biopharma stock with no revenue or FDA pipeline. However, the stock has exceptional price momentum with shares up 508% over the past year. PVLA is trading...

PVLA : 93.80 (+2.06%)
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.6000 (+0.56%)
GHRS : 15.35 (+6.75%)
TYRA : 22.11 (+1.89%)
DMAC : 8.63 (+1.41%)
XBI : 123.25 (+1.17%)
This Stock Is Up 704% in 2025 But Has No Products to Its Name

Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Shares...

RLMD : 4.00 (-1.48%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar